 The Center for Drug Evaluation of Chinas National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED China Limiteds NASDAQ: HCM amdizalisib HMPL-689. The selective and potent PI3Kδ inhibitor is being developed for relapsed or refractory follicular lymphoma FL, a subtype of non-Hodgkins lymphoma NHL. 